Pharmacokinetics-pharmacodynamics of CB-618 in combination with cefepime, ceftazidime, ceftolozane, or meropenem: The pharmacological basis for a stand-alone β-lactamase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  Ambrose, Paul G ^a   VanScoy, Brian D ^a   Trang, Michael ^a   McCauley Miller, Jennifer ^a   Conde, Haley ^a   Bhavnani, Sujata M ^a   Alexander, Dylan C ^b   Friedrich, Lawrence V ^b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CB 618; Pharmacokinetics pharmacodynamics; lactamase inhibitor

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTXM 15; BETA LACTAMASE FOX 5; BETA LACTAMASE INHIBITOR; BETA LACTAMASE KPC 2; BETA LACTAMASE KPC 3; BETA LACTAMASE OXA 1; BETA LACTAMASE OXA 30; BETA LACTAMASE OXA 48; BETA LACTAMASE SHV 1; BETA LACTAMASE SHV 11; BETA LACTAMASE SHV 27; BETA LACTAMASE TEM 1; CB 618; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; COMPUTER SIMULATION; DRUG EFFECT; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; COMPUTER SIMULATION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 85032260321     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00630-17     Document Type: Article

References (15)

1. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18:263–272. https://doi.org/10.1016/j.molmed.2012.03.003.
2. Livermore DM, Woodford N. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas, and Acinetobacter. Trends Microbiol 14: 413–420. https://doi.org/10.1016/j.tim.2006.07.008.
3. Bush K. 2010. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 13:558 –564. https://doi.org/10.1016/j.mib.2010.09.006.
4. Johnson AP, Woodford N. 2013. Global spread of antibiotic resistant: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbap-enem resistance. J Med Microbiol 62:499–513. https://doi.org/10.1099/jmm.0.052555-0.
5. Poirel L, Potron Anaïs Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrobial Chemother 67:1597–1606. https://doi.org/10.1093/jac/dks121.
6. Hospira, Inc. 2016. Maxipime package insert. Hospira, Inc, Lake Forest, IL. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?eventoverview.process&applno050679.
7. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. 2005. Comparison on the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49:1337–1339. https://doi.org/10.1128/AAC.49.4.1337-1339.2005.
8. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th ed. CLSI document M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
9. VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG. 2016. Pharmacokinetics-pharmacodynamics of a novel -lactamase inhibitor, CB-618, in combination with meropenem in an in vitro infection model. Antimicrob Agents Chemother 60:3891–3896. https://doi.org/10.1128/AAC.02943-15.
10. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
11. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809 –2814. https://doi.org/10.1128/AAC.02513-12.
12. VanScoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of -lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924–5930. https://doi.org/10.1128/AAC.00656-13.
13. AztraZeneca. 2016. Merrem (meropenem for injection) package insert. AztraZeneca, Wilmington, DE.
14. Merck & Co., Inc. 2015. Zerbaxa (ceftolozane/tazobactam for injection) package insert. Merck & Co, Inc, Whitehouse Station, NJ.
15. Covis Pharmaceuticals, Inc. 2014. Fortaz (ceftazidime for injection) package insert. Covis Pharmaceuticals Inc, Cary, NC.